[Reuters] – No serious safety concerns were raised over Merck & Co’s experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval. The Allergenic Products Advisory Committee will meet on Tuesday to review Ragwitek, a pill placed under the tongue that, if approved, would be an alternative to regular injections administered by doctors for … [visit site to read more]
- Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1
- Merck & Co. Inc. (NYSE:MRK) – FDA panel says Merck’s allergy drug effective
- Market Update on Morgan Stanley (NYSE:MS) – [video] Business side of JPM determines cash flow: Pro
